Halozyme Therapeutics, Inc. (HALO) is listed on NASDAQ in Biotech Stocks. It is $105.31, -1.51%, with a $12.0B market cap. RSI is 69.1, near overbought. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 69.1 Near Overbought
Market Cap $12.0B
Volume 1.2M
Fundamentals — 10-Q Q2 2026
Revenue $857.7M
Net Income $380.0M
EPS $3.11
Gross Margin 81.5%
Operating Margin 55.1%
Net Margin 44.3%
Debt / Equity 13.5x
P/E Ratio 33.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO | Sell | 60,000 | $104.59 | $6.3M | 2026 Aug 19 |
| Connaughton Bernadette | Director | Sell | 1,626 | $102.80 | $167,153 | 2026 Aug 10 |
| Torley Helen | PRESIDENT AND CEO | Sell | 1,923 | $79.77 | $153,391 | 2026 Jul 8 |
| Connaughton Bernadette | Director | Sell | 1,625 | $76.71 | $124,651 | 2026 Jul 1 |
| Krishnan Mahesh | Director | Sell | 7,304 | $75.00 | $547,800 | 2026 Jun 29 |
| Torley Helen | PRESIDENT AND CEO | Sell | 50,000 | $67.40 | $3.4M | 2026 Jun 3 |
| Connaughton Bernadette | Director | Sell | 1,625 | $66.21 | $107,591 | 2026 Jun 1 |
| Torley Helen | PRESIDENT AND CEO | Sell | 50,000 | $68.68 | $3.4M | 2026 May 13 |
| Connaughton Bernadette | Director | Sell | 1,625 | $63.48 | $103,155 | 2026 May 1 |
| Torley Helen | PRESIDENT AND CEO | Sell | 10,000 | $63.50 | $634,982 | 2026 Apr 6 |
| Torley Helen | PRESIDENT AND CEO | Sell | 40,000 | $64.81 | $2.6M | 2026 Apr 2 |
| Torley Helen | PRESIDENT AND CEO | Sell | 50,000 | $69.52 | $3.5M | 2026 Mar 4 |
| Connaughton Bernadette | Director | Sell | 829 | $71.60 | $59,356 | 2025 Dec 1 |
| Torley Helen | PRESIDENT AND CEO | Sell | 16,569 | $68.92 | $1.1M | 2025 Dec 1 |
| Torley Helen | PRESIDENT AND CEO | Sell | 60,000 | $69.46 | $4.2M | 2025 Nov 12 |
| Connaughton Bernadette | Director | Sell | 2,000 | $68.48 | $136,960 | 2025 Nov 10 |
| Caudill Cortney | SVP, CHIEF OPERATING OFFICER | Sell | 4,263 | $65.19 | $277,905 | 2025 Nov 1 |
| Torley Helen | PRESIDENT AND CEO | Sell | 60,000 | $71.86 | $4.3M | 2025 Oct 3 |
| Connaughton Bernadette | Director | Sell | 2,000 | $75.24 | $150,485 | 2025 Oct 1 |
| LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Sell | 2,227 | $77.95 | $173,591 | 2025 Sep 22 |
Other Biotech Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $137.93 | 63.6 | $55.1B |
| | $432.33 | 66.2 | $233.7B |
| | $145.64 | 60.3 | $180.6B |
| | $72.36 | 58.5 | $11.3B |
| | $134.97 | 69.6 | $10.2B |
| | $153.99 | 40.2 | $15.7B |
| | $102.12 | 51.7 | -- |
| | $218.46 | 60.5 | $32.3B |
Take HALO further
- Browse Biotech Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put HALO in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Halozyme Therapeutics, Inc. next reports.
Set alerts on HALO
Get notified when Halozyme Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free